Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding childrens) meta-analysis

ChAdOx1 phase 3 (AstraZeneca), 2020
 
NCT04400838
RCTVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding childrens)some concern
5807/5829 conclusif
  • demonstrated 67 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
ENSEMBLE (COV3001) unpublished
 
NCT04505722
RCTJanssen AD26 vaccine (JNJ-78436735)placeboCOVID-19 prophylaxis (excluding childrens)some concern
21895/21888 conclusif
  • suggested 81 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
  • demonstrated 67 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 82 % decrease in hospitalization with a moderate degree of certainty due to some concern in risk of bias
27 studies excluded by filtering options (12 RCT / 15 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).